CR Intrinsic Investors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

CR Intrinsic Investors’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-300,000	Closed	-$3.5M	–	196
2014 Q1	$3.5M	Buy	+300,000	New	+$5.08M	0.13%	205
2013 Q4	–	Sell	-160,000	Closed	-$2.3M	–	390
2013 Q3	$2.3M	Sell	160,000 -90,000	-36%	-$1.38M	0.07%	277
2013 Q2	$3.77M	Buy	+250,000	New	+$3.3M	0.13%	209

Other funds holding MNTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CR Intrinsic Investors's MNTA Position: Q2 2014 in Review

CR Intrinsic Investors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2014, closing a stake of 300,000 shares — an estimated $3.5M sold.

CR Intrinsic Investors first reported a position in MNTA in Q2 2013 and held it in 3 quarters. The position peaked at $3.77M in Q2 2013. 148 funds tracked by Wall St. Rank hold MNTA as of Q2 2014.

CR Intrinsic Investors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
CR Intrinsic Investors sold 300,000 Momenta Pharmaceuticals, Inc. shares in Q2 2014, an estimated $3.5M.
CR Intrinsic Investors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
CR Intrinsic Investors's Momenta Pharmaceuticals, Inc. position peaked at $3.77M in Q2 2013.
148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2014.

Based on CR Intrinsic Investors's 13F filing for Q2 2014.